会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • METHODS AND COMPOSITIONS FOR ENHANCED DELIVERY OF BIOACTIVE MOLECULES
    • 用于增强生物活性分子的方法和组合物
    • US20080292712A1
    • 2008-11-27
    • US12186203
    • 2008-08-05
    • Danny LewisPaul SchmidtKenneth Hinds
    • Danny LewisPaul SchmidtKenneth Hinds
    • A61K9/52A61K38/21A61K38/02A61K38/08A61K38/31A61P43/00
    • A61K47/6927A61K47/593A61K47/60A61K47/61
    • Formulations for controlled, prolonged release of bioactive molecules such as therapeutic proteins, peptides and oligonucleotides have been developed. These formulations are based on solid microparticles or nanoparticles formed of the combination of biodegradable, synthetic polymers such as poly (lactic acid) (PLA), poly (glycolic acid) (PGA), and copolymers thereof. Bioactive molecules are coupled to hydrophilic polymers such as polyethylene glycol or polypropylene glycol and formulated to provide controlled release. The bioactive molecules are more stable, less immunogenic and have improved release rate profiles with lower burst levels and increased drug loading relative to the same bioactive molecules lacking coupled hydrophilic polymers. The controlled release formulations can be administered by injection, by inhalation, nasally, or orally.
    • 已经开发了用于受控的,延长释放生物活性分子例如治疗性蛋白质,肽和寡核苷酸的制剂。 这些制剂基于由可生物降解的合成聚合物如聚(乳酸)(PLA),聚(乙醇酸)(PGA)及其共聚物的组合形成的固体微粒或纳米颗粒。 将生物活性分子偶联到亲水性聚合物如聚乙二醇或聚丙二醇上,并配制成提供受控释放。 相对于缺乏偶联亲水聚合物的相同生物活性分子,生物活性分子更稳定,免疫原性更小,具有更低的爆发水平和更高的药物负载量的改善的释放速率分布。 控制释放制剂可以通过注射,吸入,鼻腔或口服给药。
    • 4. 发明授权
    • Methods and compositions for enhanced delivery of bioactive molecules
    • 用于增强生物活性分子递送的方法和组合物
    • US06706289B2
    • 2004-03-16
    • US09999820
    • 2001-10-31
    • Danny LewisPaul SchmidtKenneth Hinds
    • Danny LewisPaul SchmidtKenneth Hinds
    • A61F202
    • A61K47/6927A61K47/593A61K47/60A61K47/61
    • Formulations for controlled, prolonged release of bioactive molecules such as therapeutic proteins, peptides and oligonucleotides have been developed. These formulations are based on solid microparticles or nanoparticles formed of the combination of biodegradable, synthetic polymers such as poly(lactic acid) (PLA), poly(glycolic acid) (PGA), and copolymers thereof. Bioactive molecules are coupled to hydrophilic polymers such as polyethylene glycol or polypropylene glycol and formulated to provide controlled release. The bioactive molecules are more stable, less immunogenic and have improved release rate profiles with lower burst levels and increased drug loading relative to the same bioactive molecules lacking coupled hydrophilic polymers. The controlled release formulations can be administered by injection, by inhalation, nasally, or orally.
    • 已经开发了用于受控的,延长释放生物活性分子例如治疗性蛋白质,肽和寡核苷酸的制剂。 这些制剂基于由可生物降解的合成聚合物如聚(乳酸)(PLA),聚(乙醇酸)(PGA)及其共聚物的组合形成的固体微粒或纳米颗粒。 将生物活性分子偶联到亲水性聚合物如聚乙二醇或聚丙二醇上,并配制成提供受控释放。 相对于缺乏偶联亲水聚合物的相同生物活性分子,生物活性分子更稳定,免疫原性更小,具有更低的爆发水平和更高的药物负载量的改善的释放速率分布。 控制释放制剂可以通过注射,吸入,鼻腔或口服给药。